Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Novo Nordisk's EVP for US Operations, Jamey Millar, is gearing up for the CMS bridge program set to launch on July 1, which will influence Medicare beneficiaries' access to obesity treatments like Wegovy. Millar expressed uncertainty about the immediate impact on patient volume, stressing the importance of educating healthcare providers and pharmacists on patient eligibility. This initiative is crucial as it could significantly influence the demand for obesity treatments, potentially boosting Novo Nordisk's market presence in the weight management sector.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.